Comparative Effectiveness of Therapies for Reducing the Risk of Primary Breast Cancer: Guidance for Shared Decision Making

AHRQ Innovations Exchange | Comparative Effectiveness of Therapies for Reducing the Risk of Primary Breast Cancer: Guidance for Shared Decision Making

 This educational program for clinicians provides information about the Agency for Healthcare Research and Quality's (AHRQ's) systematic review of the comparative effectiveness and safety of tamoxifen, raloxifene, and tibolone for reducing the risk of primary breast cancer in women.